StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

Emergent BioSolutions operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Emergent BioSolutions's operating income for the twelve months ending Sep 30, 2026 was -$179.80M, down 251.7% year over year. For fiscal 2025 it was $100.10M. Over ten years it grew -3.4% a year on average. The highest annual figure on record is $438.50M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.10M–
FY2024Dec 31, 2024-$108.70M–
FY2023Dec 31, 2023-$726.40M–
FY2022Dec 31, 2022-$170.00M-149.8%
FY2021Dec 31, 2021$341.40M-22.1%
FY2020Dec 31, 2020$438.50M+284.3%
FY2019Dec 31, 2019$114.10M+27.1%
FY2018Dec 31, 2018$89.80M-27.8%
FY2017Dec 31, 2017$124.30M+17.8%
FY2016Dec 31, 2016$105.50M-25.4%
FY2015Dec 31, 2015$141.51M+58.7%
FY2014Dec 31, 2014$89.19M+108.4%
FY2013Dec 31, 2013$42.80M+42.8%
FY2012Dec 31, 2012$29.97M-6.6%
FY2011Dec 31, 2011$32.10M-56.4%
FY2010Dec 31, 2010$73.56M+83.2%
FY2009Dec 31, 2009$40.15M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$37.30M-148.8%
Q2 FY2026Jun 30, 2026-$125.10M-7918.8%
Q1 FY2026Mar 31, 2026$10.50M-79.0%
Q4 FY2025Dec 31, 2025-$27.90M–
Q3 FY2025Sep 30, 2025$76.50M+18.6%
Q2 FY2025Jun 30, 2025$1.60M–
Q1 FY2025Mar 31, 2025$49.90M+25.4%
Q4 FY2024Dec 31, 2024-$9.50M–
Q3 FY2024Sep 30, 2024$64.50M–
Q2 FY2024Jun 30, 2024-$203.50M–
Q1 FY2024Mar 31, 2024$39.80M–
Q4 FY2023Dec 31, 2023-$43.80M–
Q3 FY2023Sep 30, 2023-$242.10M–
Q2 FY2023Jun 30, 2023-$292.90M–
Q1 FY2023Mar 31, 2023-$147.60M-2239.1%
Q4 FY2022Dec 31, 2022-$55.30M-119.3%
Q3 FY2022Sep 30, 2022-$45.30M–
Q2 FY2022Jun 30, 2022-$76.30M-1174.6%
Q1 FY2022Mar 31, 2022$6.90M-92.5%
Q4 FY2021Dec 31, 2021$286.80M+11.1%
Q3 FY2021Sep 30, 2021-$44.70M-172.9%
Q2 FY2021Jun 30, 2021$7.10M-94.4%
Q1 FY2021Mar 31, 2021$92.20M–
Q4 FY2020Dec 31, 2020$258.10M+231.7%
Q3 FY2020Sep 30, 2020$61.30M-13.3%
Q2 FY2020Jun 30, 2020$126.00M–
Q1 FY2020Mar 31, 2020-$11.60M–
Q4 FY2019Dec 31, 2019$77.80M+594.6%
Q3 FY2019Sep 30, 2019$70.70M+231.9%
Q2 FY2019Jun 30, 2019-$7.00M-110.5%
Q1 FY2019Mar 31, 2019-$27.40M–
Q4 FY2018Dec 31, 2018$11.20M-78.9%
Q3 FY2018Sep 30, 2018$21.30M-55.4%
Q2 FY2018Jun 30, 2018$66.80M+683.2%
Q1 FY2018Mar 31, 2018-$9.50M-163.7%
Q4 FY2017Dec 31, 2017$53.09M+4.3%
Q3 FY2017Sep 30, 2017$47.77M–
Q2 FY2017Jun 30, 2017$8.53M–
Q1 FY2017Mar 31, 2017$14.91M–
Q4 FY2016Dec 31, 2016$50.91M–

More Emergent BioSolutions figures

See a number that looks wrong?